Precision BioSciences Files Ninth Patent Infringement Lawsuit Against Cellectis Related To Engineered Meganucleases

Research Triangle Park, NC (Marketwire) - Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a patent infringement lawsuit against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina. The lawsuit seeks a ruling that Cellectis' manufacture, use, sale, and importation of certain engineered meganucleases infringe U.S. Patent No. 8,148,098, which relates to Precision BioSciences' ground-breaking Directed Nuclease Editor™ genome engineering technology. The lawsuit requests monetary damages as well as a permanent injunction preventing Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the United States. Precision BioSciences previously announced that it had filed suit against Cellectis for alleged infringement of U.S. Patent Nos. 8,021,867, 8,119,381, 8,119,361, 8,124,369, 8,129,134,8,133,697, 8,143,015, and 8,143,016.

About Precision BioSciences
Precision BioSciences' mission is to continually provide, improve, and enable the world's most powerful genome engineering technology. Precision's proprietary Directed Nuclease Editor™ (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences' vision is to be the conduit through which the world's greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the world's largest biopharmaceutical, agbiotech, and animal research firms. Internally, Precision is developing applications of DNE in biological production and human therapeutics. For additional information, please visit www.precisionbiosciences.com.

SOURCE: Precision BioSciences, Inc.